Dr. John Cush RheumNow
4 years 10 months ago
Rituximab Patients May Benefit from Third COVID-19 Vaccine Dose
This abstract will be presented at 10:45am EST, Tuesday, November 9, 2021 during the Late-Breaking Abstracts session (L16 - L21). #ACR21
https://t.co/A1nAL8OnCu https://t.co/lsSyZmjfuF
Janet Pope Janetbirdope
4 years 10 months ago
#ClinicalPearl Distal fingers in #Scleroderma lose pulp. In this patient #calcinosis (chronic) caused the nail/bed to expand! @RheumNow @CRASCRRheum https://t.co/bj4cxP7q6J
Dr. John Cush RheumNow
4 years 10 months ago
I like this. Downloaded and read. Great for patients too! https://t.co/B081u0ijjU
Dr. John Cush RheumNow
4 years 10 months ago
Survey of 10,234 Dannish Primary Care pts (w/ LBP, hip or knee #OA)to Dx self reported Lumbar Spinal Stenosis (LSS) based on 11 Sxs. LSS Sxs were more in LBP (11–71%) than hip (11–50%) or knee OA (8–40%). Overall LSS seen <10% cohorts https://t.co/v9LO09IZla
Dr. John Cush RheumNow
4 years 10 months ago
But baricitinib inhibits endocytosis of the virus and thus should be antiviral early in the disease. I believe the paradox is based on who gets bari, mostly those with poorly controlled disease https://t.co/euOthMLDt3
Dr. John Cush RheumNow
4 years 10 months ago
1119 thoracic aortic surgeries - 3.7% dx as inflammatory aortitis (66% CIA, 27% GCA, 5% TAK) (20% given steroids). Aortitis were more female, older, more HTN w/ more immunosuppressives, but no diff in 30d mortality (7.3 vs 6.5%) https://t.co/94VBaRAry5
Rohit Aggarwal docrota
4 years 10 months ago
Happy Diwali to all my Twitter friends. May this festival of light glow your life with knowledge, happiness and prosperity. I also feel for all those who lost their loved one this year to Covid and may Diwali brings peace to you as well. https://t.co/xRGnuxz068
Dr. John Cush RheumNow
4 years 11 months ago
CRESPA trial pts (Golimumab in monoRx peripheral SpA) offered change to MTX. 25/60 pSpA entered the step-down to MTX, but 21/25 flared & 4 (16%) stayed in remission (others restarted GOL). MTX cant maintain GOL remission in pSpA https://t.co/zGg3UqoDqp
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that proactive therapeutic drug monitoring, a newer treatment strategy where a patient’s drug serum levels are regularly assessed to adjust the dose and intervals,
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017. (Abstract #1783).
Dr. John Cush RheumNow
4 years 11 months ago
Drug development in the USA: Did you know?
1. Typical drug development timeline is 10-15 years;
2. It cost as much as US $2.6 billion to bring a drug to market;
3. Only 0.02% of drugs in development make it to market
https://t.co/GXKddBLOUv
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine (
Dr. John Cush RheumNow
4 years 11 months ago
Management of Immune-Related Adverse Events - ASCO Guideline
https://t.co/6G8WT7ijlL
#ACR21 https://t.co/lfslvXbUQs
Dr. John Cush RheumNow
4 years 11 months ago
#ACR21 is nearly here and we want to see your best images of learning virtually, missing a meeting in San Francisco, wellness, or break time activities.
Tweet your pic and make sure to include #RheumPix and #ACR21 and we’ll RT our favorites. https://t.co/R5mCpsuMye
